497 related articles for article (PubMed ID: 29797644)
1. Sickle Cell Clinical Research and Intervention Program (SCCRIP): A lifespan cohort study for sickle cell disease progression from the pediatric stage into adulthood.
Hankins JS; Estepp JH; Hodges JR; Villavicencio MA; Robison LL; Weiss MJ; Kang G; Schreiber JE; Porter JS; Kaste SC; Saving KL; Bryant PC; Deyo JE; Nottage KA; King AA; Brandow AM; Lebensburger JD; Adesina O; Chou ST; Zemel BS; Smeltzer MP; Wang WC; Gurney JG
Pediatr Blood Cancer; 2018 Sep; 65(9):e27228. PubMed ID: 29797644
[TBL] [Abstract][Full Text] [Related]
2. Height-corrected low bone density associates with severe outcomes in sickle cell disease: SCCRIP cohort study results.
Adesina OO; Gurney JG; Kang G; Villavicencio M; Hodges JR; Chemaitilly W; Kaste SC; Zemel BS; Hankins JS
Blood Adv; 2019 May; 3(9):1476-1488. PubMed ID: 31072833
[TBL] [Abstract][Full Text] [Related]
3. Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members.
Yawn BP; Buchanan GR; Afenyi-Annan AN; Ballas SK; Hassell KL; James AH; Jordan L; Lanzkron SM; Lottenberg R; Savage WJ; Tanabe PJ; Ware RE; Murad MH; Goldsmith JC; Ortiz E; Fulwood R; Horton A; John-Sowah J
JAMA; 2014 Sep; 312(10):1033-48. PubMed ID: 25203083
[TBL] [Abstract][Full Text] [Related]
4. Prospective longitudinal follow-up of children with sickle cell disease treated with hydroxyurea since infancy.
Thomas R; Dulman R; Lewis A; Notarangelo B; Yang E
Pediatr Blood Cancer; 2019 Sep; 66(9):e27816. PubMed ID: 31157521
[TBL] [Abstract][Full Text] [Related]
5. Age-related treatment patterns in sickle cell disease patients and the associated sickle cell complications and healthcare costs.
Blinder MA; Vekeman F; Sasane M; Trahey A; Paley C; Duh MS
Pediatr Blood Cancer; 2013 May; 60(5):828-35. PubMed ID: 23335275
[TBL] [Abstract][Full Text] [Related]
6. Association of elevated tricuspid regurgitation velocity with cerebrovascular and kidney disease in children with sickle cell disease.
Ilonze C; Rai P; Galadanci N; Zahr R; Okhomina VI; Kang G; Padmanabhan D; Lebensburger J; Alishlash AS
Pediatr Blood Cancer; 2024 Jul; 71(7):e31002. PubMed ID: 38644595
[TBL] [Abstract][Full Text] [Related]
7. Survival among children and adults with sickle cell disease in Belgium: Benefit from hydroxyurea treatment.
Lê PQ; Gulbis B; Dedeken L; Dupont S; Vanderfaeillie A; Heijmans C; Huybrechts S; Devalck C; Efira A; Dresse MF; Rozen L; Benghiat FS; Ferster A
Pediatr Blood Cancer; 2015 Nov; 62(11):1956-61. PubMed ID: 26173735
[TBL] [Abstract][Full Text] [Related]
8. Chronic Administration of Hydroxyurea (HU) Benefits Caucasian Patients with Sickle-Beta Thalassemia.
Di Maggio R; Hsieh MM; Zhao X; Calvaruso G; Rigano P; Renda D; Tisdale JF; Maggio A
Int J Mol Sci; 2018 Feb; 19(3):. PubMed ID: 29495591
[TBL] [Abstract][Full Text] [Related]
9. Hydroxyurea use and hospitalization trends in a comprehensive pediatric sickle cell program.
Nottage KA; Hankins JS; Smeltzer M; Mzayek F; Wang WC; Aygun B; Gurney JG
PLoS One; 2013; 8(8):e72077. PubMed ID: 23967276
[TBL] [Abstract][Full Text] [Related]
10. Original Research: Parvovirus B19 infection in children with sickle cell disease in the hydroxyurea era.
Hankins JS; Penkert RR; Lavoie P; Tang L; Sun Y; Hurwitz JL
Exp Biol Med (Maywood); 2016 Apr; 241(7):749-54. PubMed ID: 26940953
[TBL] [Abstract][Full Text] [Related]
11. Neonatal Screening and the Clinical Outcome in Children with Sickle Cell Disease in Central India.
Upadhye DS; Jain DL; Trivedi YL; Nadkarni AH; Ghosh K; Colah RB
PLoS One; 2016; 11(1):e0147081. PubMed ID: 26785407
[TBL] [Abstract][Full Text] [Related]
12. Real-life experience with hydroxyurea in sickle cell disease: A multicenter study in a cohort of patients with heterogeneous descent.
Rigano P; De Franceschi L; Sainati L; Piga A; Piel FB; Cappellini MD; Fidone C; Masera N; Palazzi G; Gianesin B; Forni GL;
Blood Cells Mol Dis; 2018 Mar; 69():82-89. PubMed ID: 29107441
[TBL] [Abstract][Full Text] [Related]
13. Hydroxyurea use in Children with Sickle Cell Disease: Do Severely Affected Patients Use It and Does It Impact Hospitalization Outcomes?
Creary SE; Chisolm DJ; Koch TL; Zigmont VA; Lu B; O'Brien SH
Pediatr Blood Cancer; 2016 May; 63(5):844-7. PubMed ID: 26797936
[TBL] [Abstract][Full Text] [Related]
14. Encephaloduroarteriosynangiosis and encephalomyoarteriosynangiosis for treatment of moyamoya syndrome in pediatric patients with sickle cell disease.
Griessenauer CJ; Lebensburger JD; Chua MH; Fisher WS; Hilliard L; Bemrich-Stolz CJ; Howard TH; Johnston JM
J Neurosurg Pediatr; 2015 Jul; 16(1):64-73. PubMed ID: 25837886
[TBL] [Abstract][Full Text] [Related]
15. Real-world experience using hydroxyurea in children with sickle cell disease in Lilongwe, Malawi.
Mvalo T; Topazian HM; Kamthunzi P; Chen JS; Kambalame I; Mafunga P; Mumba N; Chiume M; Paseli K; Tegha G; Kumwenda W; Heimlich JB; Ellis G; Key N; Gopal S; Hoffman I; Ataga KI; Westmoreland KD
Pediatr Blood Cancer; 2019 Nov; 66(11):e27954. PubMed ID: 31397075
[TBL] [Abstract][Full Text] [Related]
16. Most adults with severe HbSC disease are not treated with hydroxyurea.
Ghunney WK; Asare EV; Ayete-Nyampong JB; Oppong SA; Rodeghier M; DeBaun MR; Olayemi E
Blood Adv; 2023 Jul; 7(13):3312-3319. PubMed ID: 36799926
[TBL] [Abstract][Full Text] [Related]
17. Treatment Options for Sickle Cell Disease.
Meier ER
Pediatr Clin North Am; 2018 Jun; 65(3):427-443. PubMed ID: 29803275
[TBL] [Abstract][Full Text] [Related]
18. A pilot study of manual chronic partial exchange transfusion in children with sickle disease.
Aloni MN; Lê PQ; Heijmans C; Huybrechts S; Devalck C; Azzi N; Ngalula-Mujinga M; Ferster A
Hematology; 2015 Jun; 20(5):284-8. PubMed ID: 25133935
[TBL] [Abstract][Full Text] [Related]
19. Neurocognitive functioning in preschool children with sickle cell disease.
Heitzer AM; Cohen DL; Okhomina VI; Trpchevska A; Potter B; Longoria J; Porter JS; Estepp JH; King A; Henley M; Kang G; Hankins JS
Pediatr Blood Cancer; 2022 Mar; 69(3):e29531. PubMed ID: 34971013
[TBL] [Abstract][Full Text] [Related]
20. Madrid Newborn Sickle Cell Disease Cohort: clinical outcomes, stroke prevention and survival.
García-Morin M; Bardón-Cancho EJ; Beléndez C; Dulín E; Blanco-Soto P; Puertas-López C; Prieto-Medina M; Cervera-Bravo Á; Llorente-Otones L; Pérez-Alonso V; San-Román S; Vecilla-Rivelles C; López-Rubio M; Sebastián E; Bellón JM; Cela E
Ann Hematol; 2024 Feb; 103(2):373-383. PubMed ID: 37980280
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
